825780
Alternative Names: GW-825780; HIV DNA vaccine - GSK/PowderMed; Therapeutic HIV DNA vaccine - GSK/PowderMedLatest Information Update: 02 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline; PowderMed
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Sep 2005 Profile reviewed with information available at the BIO-2005 conference
- 30 Nov 2004 Phase-I clinical trials in HIV infections treatment in England (Intradermal)
- 03 Jun 2004 PowderMed, an independent company spun off from Chiron Vaccines is now developing the HIV DNA vaccine in partnership with GlaxoSmithKline